Jefferies analyst Chris Howerton raised the price target on Cara Therapeutics (NASDAQ: CARA) to $33.00 (from $25.00) while maintaining a Buy rating.

Analyst PT Change

Cara Therapeutics (CARA) FV Target Raised to $33 at JanneyMay 29, 2019 3:40 PM Cara Therapeutics (CARA) PT Raised to $28 at H.C. WainwrightMay 29, 2019 10:55 AM Cara Therapeutics (CARA) PT Raised to $33 at StifelMay 29, 2019 10:53 AM Cara Therapeutics (CARA) PT Raised to $35 at Needham & CompanyMay 29, 2019 10:30 AM Cara Therapeutics (CARA) option implied volatility comes in after topline dataMay 29, 2019 10:01 AM Pre-Open Movers 05/29: (SOLY) (CARA) (AMRN) Higher; (ANF) (GOOS) (CPRI) (more...)May 29, 2019 9:28 AM Cara Therapeutics (CARA) option implied volatility elevated into announcing topline data May 29, 2019 9:23 AM Stifel Reiterates Buy Rating on Cara Therapeutics (CARA)May 29, 2019 8:23 AM Form 8-K Cara Therapeutics, Inc. For: May 29May 29, 2019 7:18 AM Cara Therapeutics (CARA) to Resume Trading at 7:30 am ETMay 29, 2019 7:04 AM Cara Therapeutics (CARA) Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus Met Primary EndpointMay 29, 2019 7:02 AM